IE 11 is not supported. For an optimal experience visit our site on another browser.

TomoTherapy Inc. is Today's Focus Stock on

/ Source: GlobeNewswire

DALLAS, March 8, 2011 (GLOBE NEWSWIRE) -- announces an investment report featuring TomoTherapy Inc. (Nasdaq:TOMO). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at:

TomoTherapy Inc. (TOMO) engages in the development, marketing and sale of advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. TOMO markets its products to hospitals and cancer treatment centers in the Americas, Europe, the Middle East and Asia-Pacific, and offers customer support services in each region directly or through third-party distributors.

For only $39 a month, you can sign up for our real-time stock alert service.  Click here to join now:

In the report, the analyst notes:

"Shares of TOMO rallied almost 25% yesterday on news that the radiation treatment company will be acquired by bigger rival Accuray Inc. for approximately $277 million - a combination expected to create a premier radiation oncology company. Accuray will acquire TOMO for $4.80 per share in cash and stock, which is nearly a 31% premium over TOMO's $3.67 closing price on Friday, March 4."

"TOMO reported revenue of $62.1 million for the fourth quarter of 2010, an increase of 7% from $58.0 million in the fourth quarter of 2009. Revenue from product sales was $48.1 million in the fourth quarter of 2010, up 8% compared to the same quarter last year, and revenue from service and other was $13.9 million in the fourth quarter of 2010, up 5% compared to the same quarter last year."

To read the entire report visit:

See what investors are saying about TOMO at

Get breaking news on TOMO at is a small-cap research and investment commentary provider. strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: Disclosure is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. is a Web site wholly owned by BlueWave Advisors, LLC. Neither nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site,, for complete risks and disclosures.

CONTACT: Brian Johnson 1-888-307-2850